Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
After hours:
| Previous close | 53.08 |
| Open | 50.96 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 43.58 - 52.50 |
| 52-week range | 12.35 - 62.21 |
| Volume | |
| Avg. volume | 1,183,159 |
| Market cap | 3.656B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.73 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.50 |
PR NewswireBiohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
Biohaven Ltd. (NYSE: BHVN) announced today that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, Colorado. The presentations highlight Biohaven's leadership in neuroscience and extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs that include Kv7 ion channel modulation, molecular
Simply Wall St.Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock
In the last year, multiple insiders have substantially increased their holdings of Biohaven Ltd. ( NYSE:BHVN ) stock...
- PR Newswire
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.
